15.80
0.00%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bonus Biogroup
Its shares trade on Tel Aviv under the ticker BONS.TA. It has been listed since 20 August 1993.
Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Aug 1993
- Employees
- 36
- Website
- bonusbiogroup.com ↗
Leadership
Pay as last reported
- Mr. Yosef RauchChairman of the Board, Vice President - Business Development, since 2012
- Dr. Shai MeretzkiChief Executive Officer, President, Director, since 2012
- Mr. Yehonatan LivneChief Financial Officer
- Daniel Ben-LuluDirector
- Ms. Batia Kahana AvitalDirector
- Mr. Yehuda ReznikDirector
- Mr. Gil ShapiraDirector
- Avi SlonimExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bonus Biogroup Ltd has a strong reputation in the market for its high-quality products and innovative solutions. The company's extensive experience in the biotechnology industry gives it a competitive edge in terms of knowledge and expertise. Additionally, the company has established a wide network of partnerships with key players in the industry, enabling it to access new markets and opportunities.
- Bonus Biogroup Ltd invests a significant amount of resources into research and development, allowing it to stay at the forefront of technological advancements in the biotech sector. This enables the company to continuously improve its products and develop innovative solutions to meet the evolving needs of its customers.
Weaknesses
- Despite its strengths, Bonus Biogroup Ltd also faces certain weaknesses that need to be addressed to maintain its competitive position. One of the main weaknesses is its limited production capacity, which makes it difficult to meet increasing customer demand. The company also lacks a strong presence in international markets, limiting its growth potential.
- Due to constraints in production capacity, Bonus Biogroup Ltd may face challenges in fulfilling large orders or meeting sudden spikes in demand. This can potentially result in missed opportunities and customer dissatisfaction.
- Although Bonus Biogroup Ltd has a strong domestic market position, it has yet to establish a significant presence in international markets. This limits the company's access to a wider customer base and potential revenue streams.
Opportunities
- Bonus Biogroup Ltd operates in an industry with significant growth potential, presenting several opportunities for future expansion. One such opportunity is the increasing demand for biotech products and solutions worldwide. The company can tap into this demand by expanding its market reach and establishing strategic partnerships with international distributors.
- As advancements in biotechnology continue, the demand for biotech solutions is expected to rise. Bonus Biogroup Ltd can leverage this opportunity by developing new products and solutions that address emerging market needs.
Threats
- Bonus Biogroup Ltd operates in a highly competitive industry and faces several threats that could impact its growth and profitability. One of the main threats is the presence of larger and more established competitors with greater resources and market share. This makes it challenging for Bonus Biogroup Ltd to differentiate itself and capture a larger market share.
- The biotech industry is highly competitive, with numerous players vying for market dominance. Bonus Biogroup Ltd needs to continuously innovate and differentiate itself to stay competitive and attract and retain customers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.